Related Experiment Video
Updated: Feb 16, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review
Maria Fernanda Avila-Vazquez1,2, Nelly F Altamirano-Bustamante3, Myriam M Altamirano-Bustamante4
1Unidad de Investigación en Enfermedades Metabólicas, Centro Médico Nacional Siglo XXI, IMSS, Mexico City 06720, Mexico. feravilaibero@gmail.com.
Abstract:
Conformational diseases represent a new aspect of proteomic medicine where diagnostic and therapeutic paradigms are evolving. In this context, the early biomarkers for target cell failure (neurons, β-cells, etc.) represent a challenge to translational medicine and play a multidimensional role as biomarkers and potential therapeutic targets. This systematic review, which follows the PICO and Prisma methods, analyses this new-fangled multidimensionality, its strengths and limitations, and presents the future possibilities it opens up. The nuclear diagnosis methods are immunoassays: ELISA, immunodot, western blot, etc., while the therapeutic approach is focused on pharmaco- and molecular chaperones.
Insights
Early biomarkers for conformational diseases are crucial in proteomic medicine. This review explores their diagnostic and therapeutic roles, highlighting immunoassays and chaperone-based treatments.
Area of Science:
- Proteomic medicine
- Translational medicine
- Biomarker discovery
Background:
- Conformational diseases are a growing area in proteomic medicine.
- Early biomarkers for target cell failure are challenging but vital for translational medicine.
- These biomarkers possess a multidimensional role as diagnostic indicators and therapeutic targets.
Purpose of the Study:
- To systematically review the multidimensionality of early biomarkers in conformational diseases.
- To analyze the strengths and limitations of current diagnostic and therapeutic approaches.
- To explore future possibilities in this evolving field.
Main Methods:
- Systematic review following PICO and Prisma methodologies.
- Analysis of nuclear diagnostic methods including immunoassays (ELISA, immunodot, western blot).
- Evaluation of therapeutic strategies focusing on pharmacochaperones and molecular chaperones.
Main Results:
- Early biomarkers play a dual role in diagnosis and therapy for conformational diseases.
- Immunoassays are key nuclear diagnostic tools.
- Pharmacochaperones and molecular chaperones represent promising therapeutic avenues.
Conclusions:
- Conformational diseases require evolving diagnostic and therapeutic paradigms.
- The multidimensionality of biomarkers offers significant potential for personalized medicine.
- Future research should focus on refining diagnostic accuracy and therapeutic efficacy of chaperones.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Conformity
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Conformations of Butane
Random and Systematic Errors

